Arrivent Biopharma, Inc. (AVBP) Stock Price & Analysis
Arrivent Biopharma, Inc. (AVBP) rose 0.60% to USD 31.73 as of July 25, 2026 at 03:09 UTC, according to Nexqual real-time market data.
AVBP last closed at USD 31.54; the session ranged USD 30.81–33.01 on volume of 462,527 shares. Market capitalization is —, with a 52-week range of USD 16.1–35.83 (NGM). Source: Nexqual, July 25, 2026 at 03:09 UTC.
Key Statistics (as of July 25, 2026 at 03:09 UTC)
| Price | USD 31.73 |
|---|---|
| Change | ▲ 0.60% (up) |
| Previous Close | USD 31.54 |
| Open | USD 31.87 |
| Day Range | USD 30.81 – 33.01 |
| 52-Week Range | USD 16.1 – 35.83 |
| Volume | 462,527 shares |
| Market Cap | — |
| Exchange | NGM |
Technical Analysis (AVBP)
Nexqual's technical model rates AVBP "NEUTRAL" based on 2 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 03:09 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.63 (neutral) |
| vs SMA50 | Above (USD 31.02) |
| MACD | -0.26 (negative) |
Analyst Ratings (AVBP)
Wall Street analysts rate AVBP "Strong Buy" based on 10 analysts, with a mean price target of USD 44.6 (range USD 42–50), per Nexqual as of July 25, 2026 at 03:09 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 44.6 |
| High Target | USD 50 |
| Low Target | USD 42 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (AVBP)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.98 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.96 vs est -0.89 ▼ miss |
| 2025-12-31 | USD -0.78 vs est -0.85 ▲ beat |
| 2025-09-30 | USD -0.83 vs est -0.78 ▼ miss |
| 2025-06-30 | USD -0.9 vs est -0.71 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
Financials & Fundamentals (AVBP)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -55.17% |
| Debt / Equity | 0.13 |
| Current Ratio | 13.95 |
| Total Cash | $326.38M |
| Total Debt | $419,000 |
| Free Cash Flow | $-82.84M |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
Financial Health Score (AVBP)
Nexqual rates Arrivent Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:09 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Strong — $326M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$134M |
| Efficiency | Critical — ROE -55%, ROA -34.7% |
Ownership (AVBP)
| Insider Ownership | +1.63% |
|---|---|
| Institutional Ownership | +96.12% |
| Float | 29.78M |
| Short % of Float | +17.43% |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
Leadership (AVBP)
Arrivent Biopharma, Inc. is led by Zhengbin Yao (age 59), Co-Founder, Chairman, President & CEO, per Nexqual as of July 25, 2026 at 03:09 UTC.
| Co-Founder, Chairman, President & CEO | Zhengbin Yao (age 59) |
|---|---|
| Co-Founder, President of Research & Development and Director | Stuart Lutzker (age 64) |
| CFO & Treasurer | Winston Kung (age 49) |
| Co-Founder & COO | Robin LaChapelle M.A. (age 52) |
| Chief Technology Officer | Yang Wang |
Major Backers & Investors (AVBP)
Notable institutional backers of Arrivent Biopharma, Inc. include Suvretta Capital Management, LLC, Infinitum Asset Management, LLC , HHLR Advisors, LTD, according to Nexqual as of July 25, 2026 at 03:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.45% |
| Infinitum Asset Management, LLC | 8.91% |
| HHLR Advisors, LTD | 8.44% |
| Orbimed Advisors LLC. | 6.5% |
| FMR, LLC | 6.48% |
| Fidelity | 5.12% |
| Octagon Capital Advisors LP | 4.23% |
| Novo Holdings A/S | 4.17% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.09% |
| Vanguard Group | 6.49% |
Source: Nexqual, July 25, 2026 at 03:09 UTC.
From Arrivent Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
- It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors.
- The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CGON | CG Oncology, Inc. | USD 69.32 | ▲ 0.01% |
| BCAX | Bicara Therapeutics Inc. | USD 27.02 | ▼ 3.36% |
| ANRO | Alto Neuroscience, Inc. | USD 26.78 | ▼ 1.65% |
| RAPP | Rapport Therapeutics, Inc. | USD 40.68 | ▼ 1.57% |
| CTNM | Contineum Therapeutics, Inc. | USD 14.06 | ▼ 4.55% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:09 UTC. This page is informational and not investment advice.